Published in Breast Cancer Res Treat on May 16, 2008
Dietary patterns and breast cancer risk in women participating in the Black Women's Health Study. Am J Clin Nutr (2009) 1.18
Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst (2014) 1.11
Cigarette smoking and postmenopausal breast cancer risk in a prospective cohort. Br J Cancer (2014) 0.88
Detoxification: a novel function of BRCA1 in tumor suppression? Toxicol Sci (2011) 0.80
A multichannel Markov random field framework for tumor segmentation with an application to classification of gene expression-based breast cancer recurrence risk. IEEE Trans Med Imaging (2012) 0.80
FGFR2 intronic SNPs and breast cancer risk: associations with tumor characteristics and interactions with exogenous exposures and other known breast cancer risk factors. Int J Cancer (2010) 0.79
BRCA1 polymorphisms and breast cancer epidemiology in the Western New York exposures and breast cancer (WEB) study. Genet Epidemiol (2013) 0.78
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 9.06
Alcohol, tobacco and breast cancer--collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer (2002) 5.83
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol (2006) 3.73
The less harmful cigarette: a controversial issue. a tribute to Ernst L. Wynder. Chem Res Toxicol (2001) 3.59
Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst (2007) 3.11
Active and passive smoking in breast cancer: prospective results from the Nurses' Health Study. Epidemiology (2002) 2.86
Carcinogenic and endocrine disrupting effects of cigarette smoke and risk of breast cancer. Lancet (2002) 2.79
Active smoking, household passive smoking, and breast cancer: evidence from the California Teachers Study. J Natl Cancer Inst (2004) 2.62
The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol (1990) 2.62
Cigarette smoking and urinary estrogens. N Engl J Med (1982) 2.55
Cigarette smoking and the risk of breast cancer in women: a review of the literature. Cancer Epidemiol Biomarkers Prev (2002) 2.39
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genes. J Natl Cancer Inst (1998) 2.33
Accumulating evidence on passive and active smoking and breast cancer risk. Int J Cancer (2005) 2.10
Breast cancer risk among women who start smoking as teenagers. Cancer Epidemiol Biomarkers Prev (2005) 1.66
Passive and active smoking and breast cancer risk in Canada, 1994-97. Cancer Causes Control (2000) 1.60
Carcinogen-DNA adducts in human breast tissue. Cancer Epidemiol Biomarkers Prev (1995) 1.40
Cigarette smoking and age at natural menopause. Am J Public Health (1980) 1.39
Active and passive cigarette smoking and the occurrence of breast cancer. Am J Epidemiol (1999) 1.38
Active and passive smoking and risk of breast cancer by age 50 years among German women. Am J Epidemiol (2002) 1.38
A prospective study of smoking and risk of breast cancer in young adult women. Cancer Epidemiol Biomarkers Prev (2004) 1.25
Cigarette smoking and the risk of endometrial cancer. N Engl J Med (1985) 1.20
Environmental carcinogens that may be involved in human breast cancer etiology. Chem Res Toxicol (1992) 1.12
Effect of weight, smoking, and estrogen use on the risk of hip and forearm fractures in postmenopausal women. Obstet Gynecol (1982) 1.09
Polycyclic aromatic hydrocarbons in human fat and liver. Bull Environ Contam Toxicol (1981) 1.06
Smoking before the birth of a first child is not associated with increased risk of breast cancer: findings from the British Women's Heart and Health Cohort Study and a meta-analysis. Br J Cancer (2004) 1.05
Diet, lifestyle and BRCA-related breast cancer risk among French-Canadians. Breast Cancer Res Treat (2006) 1.05
Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat (2006) 1.05
The role of aromatic hydrocarbons in the genesis of breast cancer. Med Hypotheses (1992) 1.04
Prospective study of smoking and the risk of breast cancer. J Natl Cancer Inst (1989) 1.01
The associations of adolescent cigarette smoking, alcoholic beverage consumption, environmental tobacco smoke, and ionizing radiation with subsequent breast cancer risk (United States). Cancer Causes Control (2000) 1.00
Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years. Breast Cancer Res Treat (2007) 1.00
Smoking and the risk of breast cancer among carriers of BRCA mutations. Int J Cancer (2004) 0.96
The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis (2005) 0.94
Cigarette smoking increases risk for breast cancer in high-risk breast cancer families. Cancer Epidemiol Biomarkers Prev (2001) 0.89
Relation of smoking to breast cancer by estrogen receptor status. Int J Cancer (1998) 0.85
Cigarette smoking and the risk of breast cancer. Eur J Cancer Prev (1996) 0.84
Cigarette smoking and breast cancer. BMJ (1995) 0.81
Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res (2007) 16.79
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst (2006) 6.73
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol (2010) 6.42
BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer (2004) 6.24
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol (2010) 6.01
Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA (2004) 5.85
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat (2008) 5.52
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med (2015) 4.77
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med (2007) 4.25
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol (2009) 4.19
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell (2011) 4.08
Improved survival in women with BRCA-associated ovarian carcinoma. Cancer (2003) 3.96
Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol (2004) 3.88
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2004) 3.86
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Familial adenomatous polyposis. Am J Gastroenterol (2006) 3.77
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2008) 3.76
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol (2006) 3.73
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol (2009) 3.59
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell (2007) 3.58
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet (2000) 3.50
Genetic structure of Europeans: a view from the North-East. PLoS One (2009) 3.46
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol (2005) 3.44
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
p27 phosphorylation by Src regulates inhibition of cyclin E-Cdk2. Cell (2007) 3.40
Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol (2005) 3.26
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25